Abstract
Maraviroc is a first-in-class selective CCR5 antagonist only approved in combination with other antiretrovirals for the treatment of HIV-infection. However, sometimes, off-label prescribing is necessary. In this regard, interesting data have been obtained with maraviroc from studies using murine models. In human daily clinical practice there are many researching areas of interest where CCR5 could play an important role. Nowadays few clinical trials are evaluating maraviroc's role in non-HIV-infected patients but there are many open issues that need to be answered about CCR5 antagonists. In this article we review some of them.
Keywords:
CCR5 antagonist; maraviroc; off-label use.
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / immunology
-
Arthritis, Rheumatoid / pathology
-
CCR5 Receptor Antagonists / therapeutic use*
-
Clinical Trials as Topic
-
Cyclohexanes / therapeutic use*
-
Graft vs Host Disease / drug therapy*
-
Graft vs Host Disease / immunology
-
Graft vs Host Disease / pathology
-
HIV Fusion Inhibitors / therapeutic use*
-
HIV Infections / drug therapy
-
HIV Infections / immunology
-
HIV Infections / virology
-
HIV-1 / drug effects
-
HIV-1 / physiology
-
Hematologic Neoplasms / drug therapy*
-
Hematologic Neoplasms / immunology
-
Hematologic Neoplasms / pathology
-
Humans
-
Maraviroc
-
Mice
-
Off-Label Use
-
Sarcoidosis / drug therapy*
-
Sarcoidosis / pathology
-
Triazoles / therapeutic use*
Substances
-
CCR5 Receptor Antagonists
-
Cyclohexanes
-
HIV Fusion Inhibitors
-
Triazoles
-
Maraviroc